PROSPECTIVE STUDY OF T3 ON THE INCIDENCE OF POSTOPERATIVE ATRIAL FIBRILLATION

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 该项目的目的是观察心脏直视手术后使用甲状腺激素（称为三碘甲状腺原氨酸或T3）治疗是否会降低发生房颤的风险。 一些接受心脏直视手术的患者可能在术后发生房颤。 房颤是一种心律失常的心脏，是最常见的术后并发症。 以前的研究表明，甲状腺激素可能会降低发生房颤的风险和额外治疗的需要。 这种药物可能会使心脏跳动更强后，离开心肺机，这是在开放的心脏手术。 如果心脏跳动更强，可能根本不需要其他心脏支持药物，或者可能需要更短的持续时间和/或更低的浓度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this project is to see whether treatment with a thyroid hormone, called triiodothyronine or T3, following open heart surgery reduces the risk of developing atrial fibrillation. Some patients who undergo open heart surgery may develop atrial fibrillation in the post-operative period. Atrial fibrillation is an arrhythmia of the heart and is the most common post-operative complication. Prior studies have suggested that thyroid hormone may reduce the risk of developing atrial fibrillation and the need for additional treatment. The medication may make the heart beat stronger after coming off the heart lung machine, which is used during open heart surgery. If the heart beats stronger, other heart support medications may not be required at all or may be required for a shorter duration and/or at lower concentrations.